|
1
|
Ortuzar A, Fox ML, Vera JA, Lorenzo Vizcaya Á, Marín Sánchez A, Llopis Calatayud I, Carbonell S, Álvarez-Larrán A, Mata Serna R, Marco Buades JE, Quiroz Cervantes K, Martínez Hellín Á, Blum Domínguez A, Caballero Navarro G, Cáceres Sansaloni A, Guerrero Fernández L, Muñoz Linares C, Gasior Kabat M, Pérez López R, Fernández Rodríguez Á, Martínez Bilbao C, Cobo Rodríguez MT, Díaz Á, Durán MA, Santaliestra Tomas M, García-Gutierrez V, Magro Mazo E, Hernández-Boluda JC, Segura A, Raya JM, Navas Elorza B, Osorio S. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain. Ann Hematol 2023; 102:447-456. [PMID: 36422672 PMCID: PMC9686214 DOI: 10.1007/s00277-022-05044-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Accepted: 11/08/2022] [Indexed: 11/25/2022]
Abstract
The SARS-CoV-2 pandemic has favored the expansion of telemedicine. Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN) might be good candidates for virtual follow-up. In this study, we aimed to analyze the follow-up of patients with Ph-MPN in Spain during COVID-19, its effectiveness, and acceptance among patients. We present a multicenter retrospective study from 30 centers. Five hundred forty-one patients were included with a median age of 67 years (yr). With a median follow-up of 19 months, 4410 appointments were recorded. The median of visits per patient was 7 and median periodicity was 2.7 months; significantly more visits and a higher frequency of them were registered in myelofibrosis (MF) patients. 60.1% of visits were in-person, 39.5% were by telephone, and 0.3% were videocall visits, with a predominance of telephone visits for essential thrombocythemia (ET) and polycythemia vera (PV) patients over MF, as well as for younger patients (< 50 yr). The proportion of phone visits significantly decreased after the first semester of the pandemic. Pharmacological modifications were performed only in 25.7% of the visits, and, considering overall management, ET patients needed fewer global treatment changes. Telephone contact effectiveness reached 90% and only 5.4% required a complementary in-person appointment. Although 56.2% of the cohort preferred in-person visits, 90.5% of our patients claimed to be satisfied with follow-up during the pandemic, with an 83% of positive comments. In view of our results, telemedicine has proven effective and efficient, and might continue to play a complementary role in Ph-MPN patients' follow-up.
Collapse
Affiliation(s)
- Ariana Ortuzar
- Hematology Department, Gregorio Marañón General University Hospital, Madrid, Spain
| | - María Laura Fox
- Hematology Department, Vall d’Hebron University Hospital, Barcelona, Spain
| | - Juan Antonio Vera
- Hematology Department, Virgen Macarena University Hospital, Seville, Spain
| | | | | | | | - Sara Carbonell
- Hematology Department, Hospital Clinic of Barcelona, Barcelona, Spain
| | | | - Raquel Mata Serna
- Hematology Department, Fundación Jiménez-Díaz University Hospital, Madrid, Spain
| | | | | | | | - Alejandra Blum Domínguez
- Hematology Department, Grupo Recoletas Hospital (Campo Grande, Zamora, Palencia Y Segovia), Palencia, Spain
| | | | | | | | | | | | - Raúl Pérez López
- Hematology Department, Clínico Virgen de La Arrixaca University Hospital, Murcia, Spain
| | | | | | | | - Álvaro Díaz
- Hematology Department, La Fe University and Polytechnic Hospital, Valencia, Spain
| | - M. Antonia Durán
- Hematology Department, Son Espases University Hospital, Palma de Mallorca, Spain
| | | | | | - Elena Magro Mazo
- Hematology Department, Príncipe de, Asturias University Hospital, Alcalá de Henares, Spain
| | | | - Adrián Segura
- Hematology Department, Doctor Negrín University Hospital, Gran Canaria, Spain
| | - José María Raya
- Hematology Department, Canarias University Hospital, Tenerife, Spain
| | | | - Santiago Osorio
- Hematology Department, Gregorio Marañón General University Hospital, Madrid, Spain
| |
Collapse
|
|
2
|
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. Cancers (Basel) 2021; 13:cancers13194750. [PMID: 34638236 PMCID: PMC8507529 DOI: 10.3390/cancers13194750] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 09/09/2021] [Accepted: 09/17/2021] [Indexed: 12/30/2022] Open
Abstract
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) started in December 2019 in China and then become pandemic in February 2020. Several publications investigated the possible increased rate of COVID-19 infection in hematological malignancies. Based on the published data, strategies for the management of chronic Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) are provided. The risk of severe COVID-19 seems high in MPN, particularly in patients with essential thrombocythemia, but not negligible in myelofibrosis. MPN patients are at high risk of both thrombotic and hemorrhagic complications and this must be accounted in the case of COVID-19 deciding on a case-by-case basis. There are currently no data to suggest that hydroxyurea or interferon may influence the risk or severity of COVID-19 infection. Conversely, while the immunosuppressive activity of ruxolitinib might pose increased risk of infection, its abrupt discontinuation during COVID-19 syndrome is associated with worse outcome. All MPN patients should receive vaccine against COVID-19; reassuring data are available on efficacy of mRNA vaccines in MPNs.
Collapse
|